CTRI/2022/04/042230已完成未知
Real world outcomes with Ribociclib in Indian patients with HR Positive, HER2 Negative Advanced Breast Cancer. - RESONATE
ovartis Healthcare Private Limited0 个研究点目标入组 410 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 410
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1. Greater than equal to 18 years old women 2. HR+ve and HER2-ve aBC diagnosis 3. Received ribociclib plus ET in line with the approved indication with at least one follow-up visit after diagnosis, or death due to any cause
排除标准
- •1. Any patient with prior/current enrollment in an interventional clinical trial for aBC/metastatic BC 2. Patient who has received another CDK4/6 inhibitor in any setting
研究者
相似试验
尚未招募
Unknown
To study the side effects and effectiveness effects of Tablet Ribociclib in hormone positive , HER2 negative breast cancer patientsCTRI/2024/01/061744ot applicable
进行中（未招募）
1 期
Ribociclib-endocrine combination therapy versus chemotherapy as 1st line treatment in patients with visceral metastatic breast cancer.A multicenter, randomized phase III trial.EUCTR2018-003648-22-ATSAKK400
招募中
1 期
Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast CancerBreast CancerNCT05996107University of Michigan Rogel Cancer Center30
进行中（未招募）
不适用
Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in FranceBreast CancerNCT05697146Novartis Pharmaceuticals1,019
已完成
不适用
The Real-World Data of Treatment with Abemaciclib for HR-positive HER2-negative Metastatic Breast Cancer: A Multicentral Cohort StudyHR-positive HER2-negative Metastatic Breast CancerJPRN-UMIN000043149Aichi Cancer Center200